HDACi - Going through the mechanisms

Frontiers in Bioscience

Volumn 16, Issue 1, 2011, Pages 340-359

  Wanczyk, Malgorzata ^a   Roszczenko, Katarzyna ^a   Marcinkiewicz, Katarzyna ^a,b   Bojarczuk, Kamil ^a   Kowara, Michal ^a   Winiarska, Magdalena ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

Author keywords

Angiogenesis; Apoptosis; Cancer; Chromatin; Histone deacetylases inhibitors; Review

Indexed keywords

ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ENZYME INHIBITOR; GELATINASE A; GELATINASE B; HEAT SHOCK PROTEIN 90; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; NUCLEAR PROTEIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

APOPTOSIS; AUTOPHAGY; CELL CYCLE; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; DRUG EFFECT; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN PROCESSING; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL CYCLE; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; REACTIVE OXYGEN SPECIES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 79955003058     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3691     Document Type: Article

References (188)

1. M. Esteller: Epigenetics in cancer. N Engl J Med, 358(11), 1148-59 (2008)
2. A. Bird: The essentials of DNA methylation. Cell, 70(1), 5-8 (1992)
3. J. M. Craig and W. A. Bickmore: The distribution of CpG islands in mammalian chromosomes. Nat Genet, 7(3), 376-82 (1994) (Pubitemid 24204413)
4. L. Shen and J. P. Issa: Epigenetics in colorectal cancer. Curr Opin Gastroenterol, 18(1), 68-73 (2002) (Pubitemid 34036528)
5. A. Agrawal, R. F. Murphy and D. K. Agrawal: DNA methylation in breast and colorectal cancers. Mod Pathol, 20(7), 711-21 (2007) (Pubitemid 46933450)
6. T. Jenuwein and CD Allis. Translating the histone code code. Science, 293(5532), 1074-80 (2001)
7. S. Y. Roth, J. M. Denu and C. D. Allis: Histone acetyltransferases. Annu Rev Biochem, 70, 81-120 (2001) (Pubitemid 32662206)
8. S. Thiagalingam, K. H. Cheng, H. J. Lee, N. Mineva, A. Thiagalingam and J. F. Ponte: Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci, 983, 84-100 (2003) (Pubitemid 36399322)
9. X. J. Yang and E. Seto: HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene, 26(37), 5310-8 (2007) (Pubitemid 47255917)
10. F. J. Dekker and H. J. Haisma: Histone acetyl transferases as emerging drug targets. Drug Discov Today, 14(19-20), 942-8 (2009)
11. F. Dal Piaz, A. Tosco, D. Eletto, A. L. Piccinelli, O. Moltedo, S. Franceschelli, G. Sbardella, P. Remondelli, L. Rastrelli, L. Vesci, C. Pisano and N. De Tommasi: The identification of a novel natural activator of p300 histone acetyltranferase provides new insights into the modulation mechanism of this enzyme. Chembiochem, 11(6), 818-27 (2010)
12. F. Manzo, F. P. Tambaro, A. Mai and L. Altucci: Histone acetyltransferase inhibitors and preclinical studies. Expert Opin Ther Pat, 19(6), 761-74 (2009)
13. D. S. Schrump: Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res, 15(12), 3947-57 (2009)
14. M. A. Glozak and E. Seto: Histone deacetylases and cancer. Oncogene, 26(37), 5420-32 (2007) (Pubitemid 47255924)
15. P. A. Marks and W. S. Xu: Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem, 107(4), 600-8 (2009)
16. C. M. Grozinger and S. L. Schreiber: Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc Natl Acad Sci U S A, 97(14), 7835-40 (2000) (Pubitemid 30460734)
17. M. Martin, R. Kettmann and F. Dequiedt: Class IIa histone deacetylases: regulating the regulators. Oncogene, 26(37), 5450-67 (2007) (Pubitemid 47255927)
18. T. A. McKinsey, C. L. Zhang and E. N. Olson: MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci, 27(1), 40-7 (2002) (Pubitemid 34131624)
19. A. Verdel, S. Curtet, M. P. Brocard, S. Rousseaux, C. Lemercier, M. Yoshida and S. Khochbin: Active maintenance of mHDA2/mHDAC6 histone-deacetylase in the cytoplasm. Curr Biol, 10(12), 747-9 (2000) (Pubitemid 30437951)
20. C. Boyault, K. Sadoul, M. Pabion and S. Khochbin: HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene, 26(37), 5468-76 (2007) (Pubitemid 47255928)
21. A. L. Goldberg, P. Cascio, T. Saric and K. L. Rock: The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol, 39(3-4), 147-64 (2002) (Pubitemid 35013508)
22. Y. Kawaguchi, J. J. Kovacs, A. McLaurin, J. M. Vance, A. Ito and T. P. Yao: The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell, 115(6), 727-38 (2003) (Pubitemid 38030301)
23. A. Vaquero, R. Sternglanz and D. Reinberg: NAD+- dependent deacetylation of H4 lysine 16 by class III HDACs. Oncogene, 26(37), 5505-20 (2007) (Pubitemid 47255931)
24. L. R. Saunders and E. Verdin: Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene, 26(37), 5489-504 (2007) (Pubitemid 47255930)
25. B. Zschoernig and U. Mahlknecht: SIRTUIN 1: regulating the regulator. Biochem Biophys Res Commun, 376(2), 251-5 (2008)
26. T. Liu, P. Y. Liu and G. M. Marshall: The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res, 69(5), 1702-5 (2009)
27. X. Ma, H. H. Ezzeldin and R. B. Diasio: Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs, 69(14), 1911-34 (2009)
28. H. Ozdag, A. E. Teschendorff, A. A. Ahmed, S. J. Hyland, C. Blenkiron, L. Bobrow, A. Veerakumarasivam, G. Burtt, T. Subkhankulova, M. J. Arends, V. P. Collins, D. Bowtell, T. Kouzarides, J. D. Brenton and C. Caldas: Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics, 7, 90 (2006)
29. K. Halkidou, L. Gaughan, S. Cook, H. Y. Leung, D. E. Neal and C. N. Robson: Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate, 59(2), 177-89 (2004) (Pubitemid 38481229)
30. J. H. Choi, H. J. Kwon, B. I. Yoon, J. H. Kim, S. U. Han, H. J. Joo and D. Y. Kim: Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res, 92(12), 1300-4 (2001) (Pubitemid 34036893)
31. Z. Zhang, H. Yamashita, T. Toyama, H. Sugiura, Y. Ando, K. Mita, M. Hamaguchi, Y. Hara, S. Kobayashi and H. Iwase: Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer Res Treat, 94(1), 11-6 (2005) (Pubitemid 41416937)
32. P. Zhu, E. Martin, J. Mengwasser, P. Schlag, K. P. Janssen and M. Gottlicher: Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell, 5(5), 455-63 (2004) (Pubitemid 38610247)
33. H. Osada, Y. Tatematsu, H. Saito, Y. Yatabe, T. Mitsudomi and T. Takahashi: Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer, 112(1), 26-32 (2004) (Pubitemid 39249488)
34. B. H. Huang, M. Laban, C. H. Leung, L. Lee, C. K. Lee, M. Salto-Tellez, G. C. Raju and S. C. Hooi: Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ, 12(4), 395-404 (2005) (Pubitemid 40520691)
35. K. B. Glaser, J. Li, M. J. Staver, R. Q. Wei, D. H. Albert and S. K. Davidsen: Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun, 310(2), 529-36 (2003) (Pubitemid 37163696)
36. M. J. LaBonte, P. M. Wilson, W. Fazzone, S. Groshen, H. J. Lenz and R. D. Ladner: DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics, 2, 67 (2009)
37. L. Ellis, Y. Pan, G. K. Smyth, D. J. George, C. McCormack, R. Williams-Truax, M. Mita, J. Beck, H. Burris, G. Ryan, P. Atadja, D. Butterfoss, M. Dugan, K. Culver, R. W. Johnstone and H. M. Prince: Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res, 14(14), 4500-10 (2008)
38. D. J. Ellis, Z. K. Lawman and K. Bonham: Histone acetylation is not an accurate predictor of gene expression following treatment with histone deacetylase inhibitors. Biochem Biophys Res Commun, 367(3), 656-62 (2008)
39. A. Rada-Iglesias, S. Enroth, A. Ameur, C. M. Koch, G. K. Clelland, P. Respuela-Alonso, S. Wilcox, O. M. Dovey, P. D. Ellis, C. F. Langford, I. Dunham, J. Komorowski and C. Wadelius: Butyrate mediates decrease of histone acetylation centered on transcription start sites and downregulation of associated genes. Genome Res, 17(6), 708-19 (2007) (Pubitemid 46919708)
40. H. Matsuoka, A. Unami, T. Fujimura, T. Noto, Y. Takata, K. Yoshizawa, H. Mori, I. Aramori and S. Mutoh: Mechanisms of HDAC inhibitor-induced thrombocytopenia. Eur J Pharmacol, 571(2-3), 88-96 (2007) (Pubitemid 47379689)
41. G. Garcia-Manero, H. Yang, C. Bueso-Ramos, A. Ferrajoli, J. Cortes, W. G. Wierda, S. Faderl, C. Koller, G. Morris, G. Rosner, A. Loboda, V. R. Fantin, S. S. Randolph, J. S. Hardwick, J. F. Reilly, C. Chen, J. L. Ricker, J. P. Secrist, V. M. Richon, S. R. Frankel and H. M. Kantarjian: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood, 111(3), 1060-6 (2008) (Pubitemid 351213383)
42. V. M. Klimek, S. Fircanis, P. Maslak, I. Guernah, M. Baum, N. Wu, K. Panageas, J. J. Wright, P. P. Pandolfi and S. D. Nimer: Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res, 14(3), 826-32 (2008) (Pubitemid 351231166)
43. J. C. Byrd, G. Marcucci, M. R. Parthun, J. J. Xiao, R. B. Klisovic, M. Moran, T. S. Lin, S. Liu, A. R. Sklenar, M. E. Davis, D. M. Lucas, B. Fischer, R. Shank, S. L. Tejaswi, P. Binkley, J. Wright, K. K. Chan and M. R. Grever: A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood, 105(3), 959-67 (2005) (Pubitemid 40170861)
44. W. Blum, R. B. Klisovic, B. Hackanson, Z. Liu, S. Liu, H. Devine, T. Vukosavljevic, L. Huynh, G. Lozanski, C. Kefauver, C. Plass, S. M. Devine, N. A. Heerema, A. Murgo, K. K. Chan, M. R. Grever, J. C. Byrd and G. Marcucci: Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol, 25(25), 3884-91 (2007) (Pubitemid 47477265)
45. S. S. Ramalingam, R. A. Parise, R. K. Ramanathan, T. F. Lagattuta, L. A. Musguire, R. G. Stoller, D. M. Potter, A. E. Argiris, J. A. Zwiebel, M. J. Egorin and C. P. Belani: Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res, 13(12), 3605-10 (2007) (Pubitemid 46955122)
46. H. Wang and B. W. Dymock: New patented histone deacetylase inhibitors. Expert Opin Ther Pat, 19(12), 1727-57 (2009)
47. S. J. Haggarty, K. M. Koeller, J. C. Wong, C. M. Grozinger and S. L. Schreiber: Domain-selective smallmolecule inhibitor of histone deacetylase 6 (HDAC6)- mediated tubulin deacetylation. Proc Natl Acad Sci U S A, 100(8), 4389-94 (2003) (Pubitemid 36457739)
48. T. Hideshima, J. E. Bradner, J. Wong, D. Chauhan, P. Richardson, S. L. Schreiber and K. C. Anderson: Smallmolecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A, 102(24), 8567-72 (2005) (Pubitemid 40862776)
49. M. Yoshida, S. Nomura and T. Beppu: Effects of trichostatins on differentiation of murine erythroleukemia cells. Cancer Res, 47(14), 3688-91 (1987) (Pubitemid 17105709)
50. M. Yoshida, Y. Hoshikawa, K. Koseki, K. Mori and T. Beppu: Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. J Antibiot (Tokyo), 43(9), 1101-6 (1990) (Pubitemid 20324373)
51. K. V. Butler and A. P. Kozikowski: Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr Pharm Des, 14(6), 505-28 (2008) (Pubitemid 351516876)
52. N. Khan, M. Jeffers, S. Kumar, C. Hackett, F. Boldog, N. Khramtsov, X. Qian, E. Mills, S. C. Berghs, N. Carey, P. W. Finn, L. S. Collins, A. Tumber, J. W. Ritchie, P. B. Jensen, H. S. Lichenstein and M. Sehested: Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J, 409(2), 581-9 (2008) (Pubitemid 351184977)
53. R. Furumai, A. Matsuyama, N. Kobashi, K. H. Lee, M. Nishiyama, H. Nakajima, A. Tanaka, Y. Komatsu, N. Nishino, M. Yoshida and S. Horinouchi: FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res, 62(17), 4916-21 (2002) (Pubitemid 34984414)
54. M. A. Glozak, N. Sengupta, X. Zhang and E. Seto: Acetylation and deacetylation of non-histone proteins. Gene, 363, 15-23 (2005) (Pubitemid 41691888)
55. A. Ito, Y. Kawaguchi, C. H. Lai, J. J. Kovacs, Y. Higashimoto, E. Appella and T. P. Yao: MDM2-HDAC1- mediated deacetylation of p53 is required for its degradation. EMBO J, 21(22), 6236-45 (2002) (Pubitemid 35415340)
56. Y. Xu: Regulation of p53 responses by posttranslational modifications. Cell Death Differ, 10(4), 400-3 (2003) (Pubitemid 36626351)
57. S. E. Salghetti, M. Muratani, H. Wijnen, B. Futcher and W. P. Tansey: Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis. Proc Natl Acad Sci U S A, 97(7), 3118-23 (2000) (Pubitemid 30183265)
58. F. Hayakawa, M. Towatari, Y. Ozawa, A. Tomita, M. L. Privalsky and H. Saito: Functional regulation of GATA- 2 by acetylation. J Leukoc Biol, 75(3), 529-40 (2004)
59. T. Yamagata, K. Mitani, H. Oda, T. Suzuki, H. Honda, T. Asai, K. Maki, T. Nakamoto and H. Hirai: Acetylation of GATA-3 affects T-cell survival and homing to secondary lymphoid organs. EMBO J, 19(17), 4676-87 (2000)
60. M. A. Martinez-Balbas, U. M. Bauer, S. J. Nielsen, A. Brehm and T. Kouzarides: Regulation of E2F1 activity by acetylation. EMBO J, 19(4), 662-71 (2000) (Pubitemid 30093739)
61. N. Pediconi, A. Ianari, A. Costanzo, L. Belloni, R. Gallo, L. Cimino, A. Porcellini, I. Screpanti, C. Balsano, E. Alesse, A. Gulino and M. Levrero: Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol, 5(6), 552-8 (2003) (Pubitemid 36781090)
62. Y. H. Jin, E. J. Jeon, Q. L. Li, Y. H. Lee, J. K. Choi, W. J. Kim, K. Y. Lee and S. C. Bae: Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J Biol Chem, 279(28), 29409-17 (2004) (Pubitemid 38915820)
63. M. Fukuoka, H. Daitoku, M. Hatta, H. Matsuzaki, S. Umemura and A. Fukamizu: Negative regulation of forkhead transcription factor AFX (Foxo4) by CBPinduced acetylation. Int J Mol Med, 12(4), 503-8 (2003)
64. R. Wang, P. Cherukuri and J. Luo: Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J Biol Chem, 280(12), 11528-34 (2005) (Pubitemid 40418464)
65. H. Y. Cohen, S. Lavu, K. J. Bitterman, B. Hekking, T. A. Imahiyerobo, C. Miller, R. Frye, H. Ploegh, B. M. Kessler and D. A. Sinclair: Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell, 13(5), 627-38 (2004) (Pubitemid 38368121)
66. P. Bali, M. Pranpat, J. Bradner, M. Balasis, W. Fiskus, F. Guo, K. Rocha, S. Kumaraswamy, S. Boyapalle, P. Atadja, E. Seto and K. Bhalla: Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem, 280(29), 26729-34 (2005) (Pubitemid 41040705)
67. Y. Li, X. Zhang, R. D. Polakiewicz, T. P. Yao and M. J. Comb: HDAC6 is required for epidermal growth factorinduced beta-catenin nuclear localization. J Biol Chem, 283(19), 12686-90 (2008)
68. K. Darvas, S. Rosenberger, D. Brenner, C. Fritsch, N. Gmelin, P. H. Krammer and F. Rosl: Histone deacetylase inhibitor-induced sensitization to TNFalpha/TRAILmediated apoptosis in cervical carcinoma cells is dependent on HPV oncogene expression. Int J Cancer (2010)
69. N. Rivera-Del Valle, S. Gao, C. P. Miller, J. Fulbright, C. Gonzales, M. Sirisawad, S. Steggerda, J. Wheler, S. Balasubramanian and J. Chandra: PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells. Int J Cell Biol, 2010, 207420 (2010)
70. M. A. Cayo, A. K. Cayo, S. M. Jarjour and H. Chen: Sodium butyrate activates Notch1 signaling, reduces tumor markers, and induces cell cycle arrest and apoptosis in pheochromocytoma. Am J Transl Res, 1(2), 178-83 (2009)
71. S. Emanuele, M. Lauricella, D. Carlisi, B. Vassallo, A. D'Anneo, P. Di Fazio, R. Vento and G. Tesoriere: SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis, 12(7), 1327-38 (2007) (Pubitemid 46890392)
72. A. Nebbioso, N. Clarke, E. Voltz, E. Germain, C. Ambrosino, P. Bontempo, R. Alvarez, E. M. Schiavone, F. Ferrara, F. Bresciani, A. Weisz, A. R. de Lera, H. Gronemeyer and L. Altucci: Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med, 11(1), 77-84 (2005) (Pubitemid 40215841)
73. A. Insinga, S. Monestiroli, S. Ronzoni, V. Gelmetti, F. Marchesi, A. Viale, L. Altucci, C. Nervi, S. Minucci and P. G. Pelicci: Inhibitors of histone deacetylases induce tumorselective apoptosis through activation of the death receptor pathway. Nat Med, 11(1), 71-6 (2005) (Pubitemid 40215840)
74. T. Imai, S. Adachi, K. Nishijo, M. Ohgushi, M. Okada, T. Yasumi, K. Watanabe, R. Nishikomori, T. Nakayama, S. Yonehara, J. Toguchida and T. Nakahata: FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells. Oncogene, 22(58), 9231-42 (2003) (Pubitemid 38122035)
75. S. Nakata, T. Yoshida, M. Horinaka, T. Shiraishi, M. Wakada and T. Sakai: Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene, 23(37), 6261-71 (2004) (Pubitemid 39215296)
76. J. E. Bolden, M. J. Peart and R. W. Johnstone: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov, 5(9), 769-84 (2006) (Pubitemid 44348499)
77. T. E. Wood, S. Dalili, C. D. Simpson, M. A. Sukhai, R. Hurren, K. Anyiwe, X. Mao, F. Suarez Saiz, M. Gronda, Y. Eberhard, N. MacLean, T. Ketela, J. C. Reed, J. Moffat, M. D. Minden, R. A. Batey and A. D. Schimmer: Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther, 9(1), 246-56 (2010)
78. W. Xu, L. Ngo, G. Perez, M. Dokmanovic and P. A. Marks: Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci U S A, 103(42), 15540-5 (2006) (Pubitemid 44625628)
79. S. Inoue, J. Riley, T. W. Gant, M. J. Dyer and G. M. Cohen: Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia, 21(8), 1773-82 (2007) (Pubitemid 47086766)
80. R. R. Rosato, S. C. Maggio, J. A. Almenara, S. G. Payne, P. Atadja, S. Spiegel, P. Dent and S. Grant: The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol Pharmacol, 69(1), 216-25 (2006) (Pubitemid 43048908)
81. A. Edwards, J. Li, P. Atadja, K. Bhalla and E. B. Haura: Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther, 6(9), 2515-24 (2007) (Pubitemid 47480417)
82. A. A. Ruefli, M. J. Ausserlechner, D. Bernhard, V. R. Sutton, K. M. Tainton, R. Kofler, M. J. Smyth and R. W. Johnstone: The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A, 98(19), 10833-8 (2001) (Pubitemid 32878706)
83. N. Sato, T. Ohta, H. Kitagawa, M. Kayahara, I. Ninomiya, S. Fushida, T. Fujimura, G. Nishimura, K. Shimizu and K. Miwa: FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol, 24(3), 679-85 (2004)
84. T. L. Cha, M. J. Chuang, S. T. Wu, G. H. Sun, S. Y. Chang, D. S. Yu, S. M. Huang, S. K. Huan, T. C. Cheng, T. T. Chen, P. L. Fan and P. W. Hsiao: Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin Cancer Res, 15(3), 840-50 (2009)
85. X. H. Zhang, M. Rao, J. A. Loprieato, J. A. Hong, M. Zhao, G. Z. Chen, A. E. Humphries, D. M. Nguyen, J. B. Trepel, X. Yu and D. S. Schrump: Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. Cancer Biol Ther, 7(9), 1388-97 (2008)
86. A. Monks, C. D. Hose, P. Pezzoli, S. Kondapaka, G. Vansant, K. D. Petersen, M. Sehested, J. Monforte and R. H. Shoemaker: Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts. Anticancer Drugs, 20(8), 682-92 (2009)
87. X. Huang, L. Gao, S. Wang, C. K. Lee, P. Ordentlich and B. Liu: HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via downregulation of erbB3 expression. Cancer Res, 69(21), 8403-11 (2009)
88. R. K. Lindemann, A. Newbold, K. F. Whitecross, L. A. Cluse, A. J. Frew, L. Ellis, S. Williams, A. P. Wiegmans, A. E. Dear, C. L. Scott, M. Pellegrini, A. Wei, V. M. Richon, P. A. Marks, S. W. Lowe, M. J. Smyth and R. W. Johnstone: Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A, 104(19), 8071-6 (2007) (Pubitemid 47185877)
89. A. Newbold, R. K. Lindemann, L. A. Cluse, K. F. Whitecross, A. E. Dear and R. W. Johnstone: Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Mol Cancer Ther, 7(5), 1066-79 (2008)
90. Y. Zhang, M. Adachi, R. Kawamura and K. Imai: Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis. Cell Death Differ, 13(1), 129-40 (2006)
91. K. A. Strait, C. T. Warnick, C. D. Ford, B. Dabbas, E. H. Hammond and S. J. Ilstrup: Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad. Mol Cancer Ther, 4(4), 603-11 (2005) (Pubitemid 40601842)
92. W. Gu and R. G. Roeder: Activation of p53 sequencespecific DNA binding by acetylation of the p53 C-terminal domain. Cell, 90(4), 595-606 (1997) (Pubitemid 27357952)
93. Y. H. Wang, Y. G. Tsay, B. C. Tan, W. Y. Lo and S. C. Lee: Identification and characterization of a novel p300- mediated p53 acetylation site, lysine 305. J Biol Chem, 278(28), 25568-76 (2003) (Pubitemid 36835309)
94. L. Feng, T. Lin, H. Uranishi, W. Gu and Y. Xu: Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol, 25(13), 5389-95 (2005) (Pubitemid 40853576)
95. K. A. Krummel, C. J. Lee, F. Toledo and G. M. Wahl: The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci U S A, 102(29), 10188-93 (2005) (Pubitemid 41023347)
96. M. V. Blagosklonny, S. Trostel, G. Kayastha, Z. N. Demidenko, L. T. Vassilev, L. Y. Romanova, S. Bates and T. Fojo: Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res, 65(16), 7386-92 (2005) (Pubitemid 41161272)
97. L. Fuino, P. Bali, S. Wittmann, S. Donapaty, F. Guo, H. Yamaguchi, H. G. Wang, P. Atadja and K. Bhalla: Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther, 2(10), 971-84 (2003)
98. R. Nimmanapalli, L. Fuino, P. Bali, M. Gasparetto, M. Glozak, J. Tao, L. Moscinski, C. Smith, J. Wu, R. Jove, P. Atadja and K. Bhalla: Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res, 63(16), 5126-35 (2003) (Pubitemid 37022654)
99. X. Yu, Z. S. Guo, M. G. Marcu, L. Neckers, D. M. Nguyen, G. A. Chen and D. S. Schrump: Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst, 94(7), 504-13 (2002) (Pubitemid 34411289)
100. J. S. Ungerstedt, Y. Sowa, W. S. Xu, Y. Shao, M. Dokmanovic, G. Perez, L. Ngo, A. Holmgren, X. Jiang and P. A. Marks: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A, 102(3), 673-8 (2005) (Pubitemid 40282724)
101. R. R. Rosato, J. A. Almenara and S. Grant: The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res, 63(13), 3637-45 (2003) (Pubitemid 36793047)
102. R. R. Rosato, J. A. Almenara, S. C. Maggio, S. Coe, P. Atadja, P. Dent and S. Grant: Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Mol Cancer Ther, 7(10), 3285-97 (2008)
103. Y. Dai, M. Rahmani, P. Dent and S. Grant: Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol, 25(13), 5429-44 (2005) (Pubitemid 40853579)
104. L. M. Butler, X. Zhou, W. S. Xu, H. I. Scher, R. A. Rifkind, P. A. Marks and V. M. Richon: The histone deacetylase inhibitor SAHA arrests cancer cell growth, upregulates thioredoxin-binding protein-2, and downregulates thioredoxin. Proc Natl Acad Sci U S A, 99(18), 11700-5 (2002) (Pubitemid 34994462)
105. G. Chen, A. Li, M. Zhao, Y. Gao, T. Zhou, Y. Xu, Z. Du, X. Zhang and X. Yu: Proteomic analysis identifies protein targets responsible for depsipeptide sensitivity in tumor cells. J Proteome Res, 7(7), 2733-42 (2008)
106. S. C. Kim, R. Sprung, Y. Chen, Y. Xu, H. Ball, J. Pei, T. Cheng, Y. Kho, H. Xiao, L. Xiao, N. V. Grishin, M. White, X. J. Yang and Y. Zhao: Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell, 23(4), 607-18 (2006) (Pubitemid 44205490)
107. R. B. Parmigiani, W. S. Xu, G. Venta-Perez, H. Erdjument-Bromage, M. Yaneva, P. Tempst and P. A. Marks: HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci U S A, 105(28), 9633-8 (2008) (Pubitemid 352031352)
108. A. Hrzenjak, M. L. Kremser, B. Strohmeier, F. Moinfar, K. Zatloukal and H. Denk: SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J Pathol, 216(4), 495-504 (2008)
109. M. Oh, I. K. Choi and H. J. Kwon: Inhibition of histone deacetylase1 induces autophagy. Biochem Biophys Res Commun, 369(4), 1179-83 (2008)
110. S. Yamamoto, K. Tanaka, R. Sakimura, T. Okada, T. Nakamura, Y. Li, M. Takasaki, Y. Nakabeppu and Y. Iwamoto: Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Res, 28(3A), 1585-91 (2008) (Pubitemid 351892934)
111. A. Eisenberg-Lerner and A. Kimchi: The paradox of autophagy and its implication in cancer etiology and therapy. Apoptosis, 14(4), 376-91 (2009)
112. N. Takai, J. C. Desmond, T. Kumagai, D. Gui, J. W. Said, S. Whittaker, I. Miyakawa and H. P. Koeffler: Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res, 10(3), 1141-9 (2004) (Pubitemid 38198916)
113. L. Liu, B. Chen, S. Qin, S. Li, X. He, S. Qiu, W. Zhao and H. Zhao: A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells. Biochem Biophys Res Commun (2010)
114. J. Kim, H. Park, J. Y. Im, W. S. Choi and H. S. Kim: Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells. Anticancer Res, 27(5A), 3285-92 (2007) (Pubitemid 47607553)
115. E. J. Lee, B. B. Lee, S. J. Kim, Y. D. Park, J. Park and D. H. Kim: Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells. Int J Oncol, 33(4), 767-76 (2008)
116. M. C. Crisanti, A. F. Wallace, V. Kapoor, F. Vandermeers, M. L. Dowling, L. P. Pereira, K. Coleman, B. G. Campling, Z. G. Fridlender, G. D. Kao and S. M. Albelda: The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther, 8(8), 2221-31 (2009)
117. J. A. Vrana, R. H. Decker, C. R. Johnson, Z. Wang, W. D. Jarvis, V. M. Richon, M. Ehinger, P. B. Fisher and S. Grant: Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene, 18(50), 7016-25 (1999) (Pubitemid 30028872)
118. V. M. Richon, T. W. Sandhoff, R. A. Rifkind and P. A. Marks: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A, 97(18), 10014-9 (2000)
119. V. Sandor, A. Senderowicz, S. Mertins, D. Sackett, E. Sausville, M. V. Blagosklonny and S. E. Bates: P21- dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer, 83(6), 817-25 (2000)
120. L. Qiu, A. Burgess, D. P. Fairlie, H. Leonard, P. G. Parsons and B. G. Gabrielli: Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell, 11(6), 2069-83 (2000) (Pubitemid 30408065)
121. J. H. Min, H. Yang, M. Ivan, F. Gertler, W. G. Kaelin, Jr. and N. P. Pavletich: Structure of an HIF- 1alpha -pVHL complex: hydroxyproline recognition in signaling. Science, 296(5574), 1886-9 (2002) (Pubitemid 34596278)
122. J. Yang, I. Ledaki, H. Turley, K. C. Gatter, J. C. Montero, J. L. Li and A. L. Harris: Role of hypoxiainducible factors in epigenetic regulation via histone demethylases. Ann N Y Acad Sci, 1177, 185-97 (2009)
123. J. E. Nor, J. Christensen, D. J. Mooney and P. J. Polverini: Vascular endothelial growth factor (VEGF)- mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol, 154(2), 375-84 (1999) (Pubitemid 29094088)
124. H. M. Verheul, B. Salumbides, K. Van Erp, H. Hammers, D. Z. Qian, T. Sanni, P. Atadja and R. Pili: Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res, 14(11), 3589-97 (2008)
125. M. C. Brahimi-Horn and J. Pouyssegur: The hypoxiainducible factor and tumor progression along the angiogenic pathway. Int Rev Cytol, 242, 157-213 (2005)
126. T. Schmid, J. Zhou, R. Kohl and B. Brune: p300 relieves p53-evoked transcriptional repression of hypoxiainducible factor-1 (HIF-1). Biochem J, 380(Pt 1), 289-95 (2004) (Pubitemid 38725754)
127. P. C. Mahon, K. Hirota and G. L. Semenza: FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev, 15(20), 2675-86 (2001) (Pubitemid 32988878)
128. M. S. Kim, H. J. Kwon, Y. M. Lee, J. H. Baek, J. E. Jang, S. W. Lee, E. J. Moon, H. S. Kim, S. K. Lee, H. Y. Chung, C. W. Kim and K. W. Kim: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med, 7(4), 437-43 (2001) (Pubitemid 32298546)
129. D. Z. Qian, S. K. Kachhap, S. J. Collis, H. M. Verheul, M. A. Carducci, P. Atadja and R. Pili: Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res, 66(17), 8814-21 (2006) (Pubitemid 44449199)
130. H. Kato, S. Tamamizu-Kato and F. Shibasaki: Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. J Biol Chem, 279(40), 41966-74 (2004) (Pubitemid 39313647)
131. D. M. Fath, X. Kong, D. Liang, Z. Lin, A. Chou, Y. Jiang, J. Fang, J. Caro and N. Sang: Histone deacetylase inhibitors repress the transactivation potential of hypoxiainducible factors independently of direct acetylation of HIF-alpha. J Biol Chem, 281(19), 13612-9 (2006) (Pubitemid 43855276)
132. S. H. Kim, J. W. Jeong, J. A. Park, J. W. Lee, J. H. Seo, B. K. Jung, M. K. Bae and K. W. Kim: Regulation of the HIF-1alpha stability by histone deacetylases. Oncol Rep, 17(3), 647-51 (2007)
133. C. F. Deroanne, K. Bonjean, S. Servotte, L. Devy, A. Colige, N. Clausse, S. Blacher, E. Verdin, J. M. Foidart, B. V. Nusgens and V. Castronovo: Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene, 21(3), 427-36 (2002) (Pubitemid 34123805)
134. Y. Sasakawa, Y. Naoe, T. Noto, T. Inoue, T. Sasakawa, M. Matsuo, T. Manda and S. Mutoh: Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol, 66(6), 897-906 (2003) (Pubitemid 37083586)
135. D. Z. Qian, Y. Kato, S. Shabbeer, Y. Wei, H. M. Verheul, B. Salumbides, T. Sanni, P. Atadja and R. Pili: Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res, 12(2), 634-42 (2006) (Pubitemid 43166159)
136. H. Ura, R. D. Bonfil, R. Reich, R. Reddel, A. Pfeifer, C. C. Harris and A. J. Klein-Szanto: Expression of type IV collagenase and procollagen genes and its correlation with the tumorigenic, invasive, and metastatic abilities of oncogene-transformed human bronchial epithelial cells. Cancer Res, 49(16), 4615-21 (1989) (Pubitemid 19208369)
137. S. H. Kim, S. Ahn, J. W. Han, H. W. Lee, H. Y. Lee, Y. W. Lee, M. R. Kim, K. W. Kim, W. B. Kim and S. Hong: Apicidin is a histone deacetylase inhibitor with antiinvasive and anti-angiogenic potentials. Biochem Biophys Res Commun, 315(4), 964-70 (2004) (Pubitemid 38249397)
138. C. Takahashi, Z. Sheng, T. P. Horan, H. Kitayama, M. Maki, K. Hitomi, Y. Kitaura, S. Takai, R. M. Sasahara, A. Horimoto, Y. Ikawa, B. J. Ratzkin, T. Arakawa and M. Noda: Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci U S A, 95(22), 13221-6 (1998) (Pubitemid 28509552)
139. K. Furumoto, S. Arii, A. Mori, H. Furuyama, M. J. Gorrin Rivas, T. Nakao, N. Isobe, T. Murata, C. Takahashi, M. Noda and M. Imamura: RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing- cysteine-rich protein with Kazal motifs. Hepatology, 33(1), 189-95 (2001) (Pubitemid 32016901)
140. L. T. Liu, H. C. Chang, L. C. Chiang and W. C. Hung: Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res, 63(12), 3069-72 (2003)
141. A. Luque, D. R. Carpizo and M. L. Iruela-Arispe: ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J Biol Chem, 278(26), 23656-65 (2003) (Pubitemid 36830188)
142. C. W. Chou and C. C. Chen: HDAC inhibition upregulates the expression of angiostatic ADAMTS1. FEBS Lett, 582(29), 4059-65 (2008)
143. S. T. Avecilla, K. Hattori, B. Heissig, R. Tejada, F. Liao, K. Shido, D. K. Jin, S. Dias, F. Zhang, T. E. Hartman, N. R. Hackett, R. G. Crystal, L. Witte, D. J. Hicklin, P. Bohlen, D. Eaton, D. Lyden, F. de Sauvage and S. Rafii: Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med, 10(1), 64-71 (2004) (Pubitemid 38524700)
144. T. Murohara, T. Asahara, M. Silver, C. Bauters, H. Masuda, C. Kalka, M. Kearney, D. Chen, J. F. Symes, M. C. Fishman, P. L. Huang and J. M. Isner: Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest, 101(11), 2567-78 (1998) (Pubitemid 28270451)
145. L. Rossig, H. Li, B. Fisslthaler, C. Urbich, I. Fleming, U. Forstermann, A. M. Zeiher and S. Dimmeler: Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res, 91(9), 837-44 (2002) (Pubitemid 35285082)
146. B. Seliger, U. Ritz, R. Abele, M. Bock, R. Tampe, G. Sutter, I. Drexler, C. Huber and S. Ferrone: Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res, 61(24), 8647-50 (2001) (Pubitemid 34013870)
147. A. F. Setiadi, M. D. David, S. S. Chen, J. Hiscott and W. A. Jefferies: Identification of mechanisms underlying transporter associated with antigen processing deficiency in metastatic murine carcinomas. Cancer Res, 65(16), 7485-92 (2005) (Pubitemid 41161284)
148. W. J. Magner, A. L. Kazim, C. Stewart, M. A. Romano, G. Catalano, C. Grande, N. Keiser, F. Santaniello and T. B. Tomasi: Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol, 165(12), 7017-24 (2000) (Pubitemid 32001174)
149. T. Maeda, M. Towatari, H. Kosugi and H. Saito: Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood, 96(12), 3847-56 (2000)
150. A. N. Khan, W. J. Magner and T. B. Tomasi: An epigenetic vaccine model active in the prevention and treatment of melanoma. J Transl Med, 5, 64 (2007)
151. S. Armeanu, M. Bitzer, U. M. Lauer, S. Venturelli, A. Pathil, M. Krusch, S. Kaiser, J. Jobst, I. Smirnow, A. Wagner, A. Steinle and H. R. Salih: Natural killer cellmediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res, 65(14), 6321-9 (2005) (Pubitemid 40994418)
152. C. Zhang, Y. Wang, Z. Zhou, J. Zhang and Z. Tian: Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother, 58(8), 1275-85 (2009)
153. D. E. Oppenheim, S. J. Roberts, S. L. Clarke, R. Filler, J. M. Lewis, R. E. Tigelaar, M. Girardi and A. C. Hayday: Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol, 6(9), 928-37 (2005) (Pubitemid 43090448)
154. C. Zhang, J. Zhang, J. Niu and Z. Tian: Interleukin- 15 improves cytotoxicity of natural killer cells via upregulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation. Cytokine, 42(1), 128-36 (2008)
155. C. Zhang, J. Zhang, J. Niu, Z. Zhou and Z. Tian: Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D. Hum Immunol, 69(8), 490-500 (2008)
156. K. Hede: Histone deacetylase inhibitors sit at crossroads of diet, aging, cancer. J Natl Cancer Inst, 98(6), 377-9 (2006)
157. G. D. Kim, Y. H. Choi, A. Dimtchev, S. J. Jeong, A. Dritschilo and M. Jung: Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase. J Biol Chem, 274(44), 31127-30 (1999)
158. C. J. Bakkenist and M. B. Kastan: DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature, 421(6922), 499-506 (2003) (Pubitemid 36168436)
159. A. Munshi, J. F. Kurland, T. Nishikawa, T. Tanaka, M. L. Hobbs, S. L. Tucker, S. Ismail, C. Stevens and R. E. Meyn: Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res, 11(13), 4912-22 (2005) (Pubitemid 41557212)
160. N. Batty, G. G. Malouf and J. P. Issa: Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett, 280(2), 192-200 (2009)
161. S. C. Dowdy, S. Jiang, X. C. Zhou, X. Hou, F. Jin, K. C. Podratz and S. W. Jiang: Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther, 5(11), 2767-76 (2006) (Pubitemid 44849003)
162. B. Sarcar, S. Kahali and P. Chinnaiyan: Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines. J Neurooncol (2010)
163. N. B. Arnold, N. Arkus, J. Gunn and M. Korc: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res, 13(1), 18-26 (2007) (Pubitemid 46121848)
164. H. Rikiishi, F. Shinohara, T. Sato, Y. Sato, M. Suzuki and S. Echigo: Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int J Oncol, 30(5), 1181-8 (2007)
165. S. S. Ramalingam, C. P. Belani, C. Ruel, P. Frankel, B. Gitlitz, M. Koczywas, I. Espinoza-Delgado and D. Gandara: Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol, 4(1), 97-101 (2009)
166. R. K. Ramanathan, M. J. Egorin, C. Erlichman, S. C. Remick, S. S. Ramalingam, C. Naret, J. L. Holleran, C. J. TenEyck, S. P. Ivy and C. P. Belani: Phase I pharmacokinetic and pharmacodynamic study of 17- dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol, 28(9), 1520-6 (2010)
167. M. S. Kim, M. Blake, J. H. Baek, G. Kohlhagen, Y. Pommier and F. Carrier: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res, 63(21), 7291-300 (2003) (Pubitemid 37413470)
168. F. Braiteh, A. O. Soriano, G. Garcia-Manero, D. Hong, M. M. Johnson, P. Silva Lde, H. Yang, S. Alexander, J. Wolff and R. Kurzrock: Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res, 14(19), 6296-301 (2008)
169. M. Candelaria, D. Gallardo-Rincon, C. Arce, L. Cetina, J. L. Aguilar-Ponce, O. Arrieta, A. Gonzalez-Fierro, A. Chavez- Blanco, E. de la Cruz-Hernandez, M. F. Camargo, C. Trejo- Becerril, E. Perez-Cardenas, C. Perez-Plasencia, L. Taja- Chayeb, T. Wegman-Ostrosky, A. Revilla-Vazquez and A. Duenas-Gonzalez: A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol, 18(9), 1529-38 (2007) (Pubitemid 47365487)
170. R. Nimmanapalli, L. Fuino, C. Stobaugh, V. Richon and K. Bhalla: Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinibinduced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood, 101(8), 3236-9 (2003) (Pubitemid 36858020)
171. M. De los Santos, A. Zambrano and A. Aranda: Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells. Mol Cancer Ther, 6(4), 1425-32 (2007) (Pubitemid 46712006)
172. C. Yu, M. Rahmani, D. Conrad, M. Subler, P. Dent and S. Grant: The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood, 102(10), 3765-74 (2003) (Pubitemid 37409399)
173. M. Rahmani, E. Reese, Y. Dai, C. Bauer, L. B. Kramer, M. Huang, R. Jove, P. Dent and S. Grant: Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17- demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol Pharmacol, 67(4), 1166-76 (2005) (Pubitemid 40416722)
174. X. Y. Pei, Y. Dai and S. Grant: Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res, 10(11), 3839-52 (2004) (Pubitemid 38697620)
175. C. M. Arundel, A. S. Glicksman and J. T. Leith: Enhancement of radiation injury in human colon tumor cells by the maturational agent sodium butyrate (NaB). Radiat Res, 104(3), 443-8 (1985) (Pubitemid 16146490)
176. J. T. Leith: Effects of sodium butyrate and 3- aminobenzamide on survival of Chinese hamster HA-1 cells after X irradiation. Radiat Res, 114(1), 186-91 (1988)
177. T. C. Karagiannis, K. N. Harikrishnan and A. El- Osta: The histone deacetylase inhibitor, Trichostatin A, enhances radiation sensitivity and accumulation of gammaH2A.X. Cancer Biol Ther, 4(7), 787-93 (2005) (Pubitemid 41351181)
178. K. Camphausen, D. Cerna, T. Scott, M. Sproull, W. E. Burgan, M. A. Cerra, H. Fine and P. J. Tofilon: Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer, 114(3), 380-6 (2005) (Pubitemid 40279957)
179. P. Chinnaiyan, G. Vallabhaneni, E. Armstrong, S. M. Huang and P. M. Harari: Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys, 62(1), 223-9 (2005) (Pubitemid 40591946)
180. T. C. Karagiannis and A. El-Osta: Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene, 25(28), 3885-93 (2006) (Pubitemid 43990743)
181. Y. L. Chung, A. J. Wang and L. F. Yao: Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy. Mol Cancer Ther, 3(3), 317-25 (2004)
182. W. Fiskus, R. Rao, P. Fernandez, B. Herger, Y. Yang, J. Chen, R. Kolhe, A. Mandawat, Y. Wang, R. Joshi, K. Eaton, P. Lee, P. Atadja, S. Peiper and K. Bhalla: Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitorresistant acute myeloid leukemia cells. Blood, 112(7), 2896-905 (2008)
183. N. Mitsiades, C. S. Mitsiades, P. G. Richardson, C. McMullan, V. Poulaki, G. Fanourakis, R. Schlossman, D. Chauhan, N. C. Munshi, T. Hideshima, V. M. Richon, P. A. Marks and K. C. Anderson: Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood, 101(10), 4055-62 (2003) (Pubitemid 36857886)
184. R. R. Rosato and S. Grant: Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets, 9(4), 809-24 (2005) (Pubitemid 41131680)
185. J. J. Xiao, A. B. Foraker, P. W. Swaan, S. Liu, Y. Huang, Z. Dai, J. Chen, W. Sadee, J. Byrd, G. Marcucci and K. K. Chan: Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by Pglycoprotein and multidrug resistance-associated protein 1. J Pharmacol Exp Ther, 313(1), 268-76 (2005) (Pubitemid 40411351)
186. Y. K. Kim, N. H. Kim, J. W. Hwang, Y. J. Song, Y. S. Park, D. W. Seo, H. Y. Lee, W. S. Choi, J. W. Han and S. N. Kim: Histone deacetylase inhibitor apicidin-mediated drug resistance: involvement of P-glycoprotein. Biochem Biophys Res Commun, 368(4), 959-64 (2008)
187. A. Fedier, K. J. Dedes, P. Imesch, A. O. Von Bueren and D. Fink: The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Int J Oncol, 31(3), 633-41 (2007)
188. V. R. Fantin, A. Loboda, C. P. Paweletz, R. C. Hendrickson, J. W. Pierce, J. A. Roth, L. Li, F. Gooden, S. Korenchuk, X. S. Hou, E. A. Harrington, S. Randolph, J. F. Reilly, C. M. Ware, M. E. Kadin, S. R. Frankel and V. M. Richon: Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res, 68(10), 3785-94 (2008)